Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Canadian Stroke Best Practice Recommendations: Rehabilitation, Recovery, and Community Participation following Stroke. Part One: Rehabilitation and Recovery Following Stroke; 6th Edition Update 2019.

Teasell R, Salbach NM, Foley N, Mountain A, Cameron JI, Jong A, Acerra NE, Bastasi D, Carter SL, Fung J, Halabi ML, Iruthayarajah J, Harris J, Kim E, Noland A, Pooyania S, Rochette A, Stack BD, Symcox E, Timpson D, Varghese S, Verrilli S, Gubitz G, Casaubon LK, Dowlatshahi D, Lindsay MP.

Int J Stroke. 2020 Jan 27:1747493019897843. doi: 10.1177/1747493019897843. [Epub ahead of print]

PMID:
31983296
2.

Canadian Stroke Best Practice Recommendations: Rehabilitation, Recovery, and Community Participation following Stroke. Part Two: Transitions and Community Participation Following Stroke.

Mountain A, Patrice Lindsay M, Teasell R, Salbach NM, de Jong A, Foley N, Bhogal S, Bains N, Bowes R, Cheung D, Corriveau H, Joseph L, Lesko D, Millar A, Parappilly B, Pikula A, Scarfone D, Rochette A, Taylor T, Vallentin T, Dowlatshahi D, Gubitz G, Casaubon LK, Cameron JI.

Int J Stroke. 2020 Jan 27:1747493019897847. doi: 10.1177/1747493019897847. [Epub ahead of print]

PMID:
31983292
3.

Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue following Stroke, 6th edition update 2019.

Lanctôt KL, Lindsay MP, Smith EE, Sahlas DJ, Foley N, Gubitz G, Austin M, Ball K, Bhogal S, Blake T, Herrmann N, Hogan D, Khan A, Longman S, King A, Leonard C, Shoniker T, Taylor T, Teed M, de Jong A, Mountain A, Casaubon LK, Dowlatshahi D, Swartz RH; Management of Mood, Cognition and Fatigue Following Stroke Best Practice Writing Group, the Heart & Stroke Canadian Stroke Best Practices and Quality Advisory Committee; in collaboration with the Canadian Stroke Consortium.

Int J Stroke. 2019 Jun 21:1747493019847334. doi: 10.1177/1747493019847334. [Epub ahead of print]

PMID:
31221036
4.

Outcomes following limb salvage after combat hindfoot injury are inferior to delayed amputation at five years.

Bennett PM, Stevenson T, Sargeant ID, Mountain A, Penn-Barwell JG.

Bone Joint Res. 2018 Feb;7(2):131-138. doi: 10.1302/2046-3758.72.BJR-2017-0217.R2.

5.

Salvage of Combat Hindfoot Fractures in 2003-2014 UK Military.

Bennett PM, Stevenson T, Sargeant ID, Mountain A, Penn-Barwell JG.

Foot Ankle Int. 2017 Jul;38(7):745-751. doi: 10.1177/1071100717697913. Epub 2017 Mar 31.

PMID:
28362519
6.

Dermal Fenestration With Negative Pressure Wound Therapy: A Technique for Managing Soft Tissue Injuries Associated With High-Energy Complex Foot Fractures.

Poon H, Le Cocq H, Mountain AJ, Sargeant ID.

J Foot Ankle Surg. 2016 Jan-Feb;55(1):161-5. doi: 10.1053/j.jfas.2015.08.014. Epub 2015 Oct 9.

PMID:
26443232
7.

Powered wheelchair skills training for persons with stroke: a randomized controlled trial.

Mountain AD, Kirby RL, Smith C, Eskes G, Thompson K.

Am J Phys Med Rehabil. 2014 Dec;93(12):1031-43. doi: 10.1097/PHM.0000000000000229.

PMID:
25353194
8.

Weaving the tapestry of learning: simulation, standardized patients, and virtual communities.

Holland B, Landry K, Mountain A, Middlebrooks MA, Heim D, Missildine K.

Nurse Educ. 2013 Nov-Dec;38(6):269-72. doi: 10.1097/01.NNE.0000435265.53612.06.

PMID:
24157677
9.

Do QTAIM metrics correlate with the strength of heavy element-ligand bonds?

Mountain AR, Kaltsoyannis N.

Dalton Trans. 2013 Oct 7;42(37):13477-86. doi: 10.1039/c3dt51337h. Epub 2013 Jul 30.

PMID:
23897486
10.

Application of topical negative pressure for traumatic amputations.

Guyver PM, Mountain AJ, Jeffery SL.

Ann R Coll Surg Engl. 2013 Apr;95(3):226-7. doi: 10.1308/003588413X13511609958532f. No abstract available.

11.

Mortality and re-operation rate after proximal femoral fracture surgery by trainees.

Khunda A, Jafari M, Alazzawi S, Mountain A, Hui AC.

J Orthop Surg (Hong Kong). 2013 Apr;21(1):87-91.

PMID:
23629996
12.

A retrospective study into the levels of evidence presented at the Combined Services Orthopaedic Society annual meeting.

Bonner TJ, Mountain A, Eardley WG, Clasper JC.

J R Army Med Corps. 2011 Sep;157(3):233-6.

PMID:
21977713
13.

Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.

Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH, Sagona J, Rigopoulos A, Smyth FE, Johns TG, Govindan SV, Goldenberg DM, Old LJ, Scott AM.

J Nucl Med. 2010 Jun;51(6):967-72. doi: 10.2967/jnumed.109.068395. Epub 2010 May 19.

14.

Improvised skeletal traction in the management of ballistic femoral fractures.

Boyd MC, Mountain AJ, Clasper JC.

J R Army Med Corps. 2009 Sep;155(3):194-6.

PMID:
20397358
15.

Rates and predictors of manual and powered wheelchair use for persons with stroke: a retrospective study in a Canadian rehabilitation center.

Mountain AD, Kirby RL, MacLeod DA, Thompson K.

Arch Phys Med Rehabil. 2010 Apr;91(4):639-43. doi: 10.1016/j.apmr.2009.11.025.

PMID:
20382299
16.

Ability of people with stroke to learn powered wheelchair skills: a pilot study.

Mountain AD, Kirby RL, Eskes GA, Smith C, Duncan H, MacLeod DA, Thompson K.

Arch Phys Med Rehabil. 2010 Apr;91(4):596-601. doi: 10.1016/j.apmr.2009.12.011.

PMID:
20382293
17.

Management of a complex hind foot war injury with negative pressure wound therapy: a case study.

Bonner TJ, Mountain A, Allison K, Sargent I, Adedapo S.

Foot (Edinb). 2009 Sep;19(3):177-80. doi: 10.1016/j.foot.2008.12.003. Epub 2009 Jan 30.

PMID:
20307472
18.

Are wheelchair-skills assessment and training relevant for long-standing wheelchair users? Two case reports.

Mountain AD, Smith C, Kirby RL.

Disabil Rehabil Assist Technol. 2010 May;5(3):230-3. doi: 10.3109/17483100903391145.

PMID:
20131977
19.

Penetrating pelvic battlefield trauma: internal use of chitosan-based haemostatic dressings.

Morrison JJ, Mountain AJ, Galbraith KA, Clasper JC.

Injury. 2010 Feb;41(2):239-41. doi: 10.1016/j.injury.2009.10.023. Epub 2009 Nov 14. No abstract available.

PMID:
19913787
20.

Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.

Lawrentschuk N, Lee FT, Jones G, Rigopoulos A, Mountain A, O'Keefe G, Papenfuss AT, Bolton DM, Davis ID, Scott AM.

Urol Oncol. 2011 Jul-Aug;29(4):411-20. doi: 10.1016/j.urolonc.2009.03.028. Epub 2009 Jun 12.

PMID:
19523858
21.

Skills training: an important component of powered wheelchair use.

Mountain AD, Kirby RL, Smith C.

Clin Rehabil. 2009 Mar;23(3):287. doi: 10.1177/0269215508101735. No abstract available.

PMID:
19218303
22.

Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.

Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG, Smyth FE, Brechbiel MW, Nice EC, Burgess AW, Scott AM.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7080s-7086s.

23.

Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity.

Lipinski KS, Pelech S, Mountain A, Irvine AS, Kraaij R, Bangma CH, Mills KH, Todryk SM.

Cancer Immunol Immunother. 2006 Mar;55(3):347-54. Epub 2005 Jun 17.

PMID:
16075195
24.

Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.

Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, U P, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O'keefe GJ, Burgess AW, Hoffman EW, Old LJ, Scott AM.

Clin Cancer Res. 2005 Jul 1;11(13):4818-26.

25.

CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells.

Williams S, Mustoe T, Mulcahy T, Griffiths M, Simpson D, Antoniou M, Irvine A, Mountain A, Crombie R.

BMC Biotechnol. 2005 Jun 3;5:17.

26.

A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.

Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Shochat D, Mountain A.

Bioconjug Chem. 2005 Mar-Apr;16(2):354-60.

PMID:
15769089
27.

Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.

Scott AM, Liu Z, Murone C, Johns TG, MacGregor D, Smyth FE, Lee FT, Cebon J, Davis ID, Hopkins W, Mountain AJ, Rigopoulos A, Hanai N, Old LJ.

Cancer Immun. 2005 Feb 22;5:3.

28.

Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70.

Djeha HA, Todryk SM, Pelech S, Wrighton CJ, Irvine AS, Mountain A, Lipinski KS.

Cancer Gene Ther. 2005 Jun;12(6):560-71.

PMID:
15665820
29.

Nitroreductase: a prodrug-activating enzyme for cancer gene therapy.

Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, Guise C, Jaberipour M, James ND, Mautner V, Young LS, Kerr DJ, Mountain A, White SA, Hyde EI.

Clin Exp Pharmacol Physiol. 2004 Nov;31(11):811-6. Review.

PMID:
15566399
30.

Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy.

Lipinski KS, Djeha HA, Gawn J, Cliffe S, Maitland NJ, Palmer DH, Mountain A, Irvine AS, Wrighton CJ.

Mol Ther. 2004 Jul;10(1):150-61.

31.

The wheelchair skills test (version 2.4): measurement properties.

Kirby RL, Dupuis DJ, Macphee AH, Coolen AL, Smith C, Best KL, Newton AM, Mountain AD, Macleod DA, Bonaparte JP.

Arch Phys Med Rehabil. 2004 May;85(5):794-804.

PMID:
15129405
32.

Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.

Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill S, Harris PA, Searle PF, Young LS, James ND, Kerr DJ.

J Clin Oncol. 2004 May 1;22(9):1546-52. Epub 2004 Mar 29.

PMID:
15051757
33.

The wheelchair skills test, version 2.4: Validity of an algorithm-based questionnaire version.

Mountain AD, Kirby RL, Smith C.

Arch Phys Med Rehabil. 2004 Mar;85(3):416-23.

PMID:
15031827
34.

Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing.

Antoniou M, Harland L, Mustoe T, Williams S, Holdstock J, Yague E, Mulcahy T, Griffiths M, Edwards S, Ioannou PA, Mountain A, Crombie R.

Genomics. 2003 Sep;82(3):269-79.

PMID:
12906852
35.

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I.

Bioconjug Chem. 2002 Jan-Feb;13(1):47-58.

PMID:
11792178
36.

High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue.

Lipinski KS, Djeha AH, Ismail T, Mountain A, Young LS, Wrighton CJ.

Mol Ther. 2001 Oct;4(4):365-71.

37.

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system.

Renner C, Stehle I, Lee FT, Hall C, Catimel B, Nice EC, Mountain A, Rigopoulos A, Brechbiel MW, Pfreundschuh M, Scott AM.

Cancer Immunol Immunother. 2001 Apr;50(2):102-8.

PMID:
11401024
38.

Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.

Lipinski KS, Djeha AH, Krausz E, Lane DP, Searle PF, Mountain A, Wrighton CJ.

Gene Ther. 2001 Feb;8(4):274-81.

39.

CL22 - a novel cationic peptide for efficient transfection of mammalian cells.

Haines AM, Irvine AS, Mountain A, Charlesworth J, Farrow NA, Husain RD, Hyde H, Ketteringham H, McDermott RH, Mulcahy AF, Mustoe TL, Reid SC, Rouquette M, Shaw JC, Thatcher DR, Welsh JH, Williams DE, Zauner W, Phillips RO.

Gene Ther. 2001 Jan;8(2):99-110.

40.

Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.

Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ, Harris PA, Mountain A, Wrighton CJ.

Mol Ther. 2001 Feb;3(2):233-40.

41.

Efficient nonviral transfection of dendritic cells and their use for in vivo immunization.

Irvine AS, Trinder PK, Laughton DL, Ketteringham H, McDermott RH, Reid SC, Haines AM, Amir A, Husain R, Doshi R, Young LS, Mountain A.

Nat Biotechnol. 2000 Dec;18(12):1273-8.

PMID:
11101806
42.

Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.

Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ, Mountain A, Young LS, Kerr DJ, Searle PF.

Int J Cancer. 2000 Jun 15;86(6):848-54.

43.
44.

Gene therapy: the first decade.

Mountain A.

Trends Biotechnol. 2000 Mar;18(3):119-28. Review.

PMID:
10675899
46.

Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor.

An Z, Wang X, Willmott N, Chander SK, Tickle S, Docherty AJ, Mountain A, Millican AT, Morphy R, Porter JR, Epemolu RO, Kubota T, Moossa AR, Hoffman RM.

Clin Exp Metastasis. 1997 Mar;15(2):184-95.

PMID:
9062395
47.

Structure of the Fab fragment of a monoclonal antibody specific for carcinoembryonic antigen.

Banfield MJ, King DJ, Mountain A, Brady RL.

Acta Crystallogr D Biol Crystallogr. 1996 Nov 1;52(Pt 6):1107-13.

PMID:
15299570
48.

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Casey JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RH.

Br J Cancer. 1996 Nov;74(9):1397-405.

49.

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).

Antoniw P, Farnsworth AP, Turner A, Haines AM, Mountain A, Mackintosh J, Shochat D, Humm J, Welt S, Old LJ, Yarranton GT, King DJ.

Br J Cancer. 1996 Aug;74(4):513-24.

50.

Supplemental Content

Loading ...
Support Center